Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vildagliptin.

Sheridan Henness1, Susan J Keam

  • 1Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 15, 2006
PubMed
Summary
This summary is machine-generated.

Vildagliptin, a DPP-4 inhibitor, effectively lowers HbA1c in type 2 diabetes patients. It demonstrates good tolerability and is beneficial alone or with other antidiabetic drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icotrokinra: First Approval.

Drugs·2026
Same author

Ferric Maltol: Pediatric First Approval.

Paediatric drugs·2026
Same author

Sevabertinib: First Approval.

Drugs·2026
Same author

Retlirafusp Alfa: First Approval.

Drugs·2026
Same author

Zeprumetostat: First Approval.

Drugs·2025
Same author

Brensocatib: First Approval.

Drugs·2025
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is a global health concern requiring effective glycemic control.
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a key therapeutic class for T2DM management.
  • Incretin hormones play a crucial role in glucose homeostasis.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of vildagliptin in patients with type 2 diabetes.
  • To assess vildagliptin's impact on glycemic control (HbA1c) as monotherapy and in combination therapy.

Main Methods:

  • Review of data from well-designed clinical trials including monotherapy and randomized active comparator studies.
  • Assessment of vildagliptin's effect on glycosylated hemoglobin (HbA1c) levels compared to placebo and active comparators (rosiglitazone, metformin).

Related Experiment Videos

  • Evaluation of vildagliptin's safety and tolerability profile, including adverse events and hypoglycemic events.

    • Main Results:

    • Vildagliptin monotherapy significantly improved glycemic control (reduced HbA1c) compared to placebo.
    • Vildagliptin demonstrated noninferiority to rosiglitazone but not metformin in reducing HbA1c.
    • Vildagliptin showed efficacy when combined with metformin, pioglitazone, or insulin.
    • Vildagliptin was generally well-tolerated, with mild-to-moderate gastrointestinal events occurring less frequently than with metformin. Hypoglycemic events were rare.

    Conclusions:

    • Vildagliptin is an effective DPP-4 inhibitor for improving glycemic control in type 2 diabetes.
    • Vildagliptin offers a favorable safety and tolerability profile, suitable for monotherapy or combination treatment.
    • Vildagliptin represents a valuable therapeutic option in the management of type 2 diabetes mellitus.